DP-Enalapril

国家: 新西兰

语言: 英文

来源: Medsafe (Medicines Safety Authority)

有效成分:

Enalapril maleate 5mg

可用日期:

Douglas Pharmaceuticals Limited

INN（国际名称）:

Enalapril maleate 5 mg

剂量:

5 mg

药物剂型:

Tablet

组成:

Active: Enalapril maleate 5mg Excipient: Hypromellose Lactose monohydrate Maize starch Maleic acid Zinc stearate

每包单位数:

Blister pack, coated Al sheets of 10 tablets in cardboard carton, 30 tablets

类:

Prescription

处方类型:

Prescription

厂商:

Neuland Laboratories Limited

疗效迹象:

Treatment of renovascular hypertension

產品總結:

Package - Contents - Shelf Life: Blister pack, coated Al sheets of 10 tablets in cardboard carton - 30 tablets - 36 months from date of manufacture stored at or below 30°C protect from light and moisture - Blister pack, coated Al sheets of 10 tablets in cardboard carton - 90 tablets - 36 months from date of manufacture stored at or below 30°C protect from light and moisture - Blister pack, coated Al sheets of 10 tablets in cardboard carton - 1000 tablets - 36 months from date of manufacture stored at or below 30°C protect from light and moisture

授权日期:

2012-03-13

产品特点

DATA SHEET 

DP-ENALAPRIL 
Enalapril maleate tablets 5 mg, 10 mg & 20 mg 

PRESENTATION  
5 mg Tablet:  White coloured, barrel shaped, uncoated tablets having embossed with 
“5” on one side and plain on the other side. 
10 mg Tablet:  Pink coloured, barrel shaped, uncoated tablets having embossed with 
“10” on one side and plain on the other side 
20 mg Tablet:  Peach coloured, barrel shaped, uncoated tablets having embossed with 
“20” on one side and plain on the other side. 

THERAPEUTIC CLASS  
DP-Enalapril (enalapril maleate) is the maleate salt of enalapril, a derivative of two 
amino acids, L-alanine and L-prolin.  Following oral administration, enalapril is rapidly 
absorbed and then hydrolysed to enalaprilat, which is a highly specific, long acting, 
nonsulphydryl angiotensin converting enzyme inhibitor.  

INDICATIONS  
Treatment of:  
• All grades of essential hypertension.  
• Renovascular hypertension.  
• All degrees of heart failure.  
In patients with symptomatic heart failure, DP-Enalapril is also indicated to:  
- Improve survival  
- Retard the progression of heart failure  
- Reduce hospitalisation for heart failure  
• Prevention of symptomatic heart failure.  
In asymptomatic patients with left ventricular dysfunction, DP-Enalapril is 
indicated to:  
- Retard the development of symptomatic heart failure  
- Reduce hospitalisation for heart failure  
• Prevention of coronary ischaemic events in patients with left ventricular dysfunction.  

DP-Enalapril is indicated to:  
• Reduce the incidence of myocardial infarction  
• Reduce hospitalisation for unstable angina pectoris  

DOSAGE AND ADMINISTRATION  
Since absorption of DP-Enalapril tablets is not affected by food, the tablets may be